×
SCYNEXIS Total Long Term Liabilities 2013-2025 | SCYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
SCYNEXIS total long term liabilities from 2013 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
SCYNEXIS Total Long Term Liabilities 2013-2025 | SCYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
SCYNEXIS total long term liabilities from 2013 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$80.2B
Zoetis (ZTS)
$68.3B
Daiichi Sankyo, - (DSNKY)
$47.1B
Takeda Pharmaceutical (TAK)
$46.9B
BeOne Medicines - (ONC)
$32.3B
Sandoz Group AG (SDZNY)
$26.4B
Summit Therapeutics (SMMT)
$20.8B
Merck (MKKGY)
$17.3B
Shionogi (SGIOY)
$14.5B
United Therapeutics (UTHR)
$13.8B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.9B
Stevanato Group S.p.A (STVN)
$7.7B
Corcept Therapeutics (CORT)
$7.3B
Madrigal Pharmaceuticals (MDGL)
$6.8B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$3.1B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Procaps Group, S.A (PROCF)
$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.9B
BioCryst Pharmaceuticals (BCRX)
$1.8B